Arcutis Biotherapeutics Inc (ARQT) returns
Arcutis Biotherapeutics returns over 5 years
$1,000 invested in Arcutis Biotherapeutics five years ago was worth $1,514 at the close on October 30, 2026, with dividends reinvested: an average return of 8.7% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | +21.3% | — | $1,213 | -0.9% |
| 3 months | +14.6% | — | $1,146 | +2.1% |
| Year to date | +10.4% | — | $1,104 | +11.7% |
| 1 year | +28.7% | — | $1,287 | +12.4% |
| 3 years | +1,294% | +140.7% | $13,943 | +88.5% |
| 5 years | +51.4% | +8.7% | $1,514 | +76.0% |
Arcutis Biotherapeutics return by calendar year
| Year | ARQT | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | +10.4% | +11.7% | -1.3% |
| 2025 | +108.5% | +17.7% | +90.8% |
| 2024 | +331.3% | +24.9% | +306.4% |
| 2023 | -78.2% | +26.2% | -104.4% |
| 2022 | -28.6% | -18.2% | -10.5% |
| 2021 | -26.3% | +28.7% | -55.0% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: ARQT financials · ARQT valuation
No forecast, no recommendation. This page describes Arcutis Biotherapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.